Description

Lantus Solostar Solution for Injections 100 IU/ml. 3 ml. №5 Cartridge

Ingredients:

Lantus Solostar contains insulin glargine, glycerol, meta-cresol, zinc oxide, and water for injections.

Mechanism of Action:

Insulin glargine in Lantus Solostar lowers blood glucose levels by enhancing cellular glucose uptake and inhibiting hepatic glucose production. Its extended action provides a basal insulin release pattern.

Pharmacological Properties:

Lantus Solostar effectively controls blood sugar levels over an extended period, aiding in glycemic control in patients with diabetes mellitus.

Indications for Use:

Lantus Solostar is indicated for the treatment of diabetes mellitus in adults, adolescents, and children aged 2 years and above to maintain optimal blood glucose levels.

Contraindications:

Do not use Lantus Solostar if allergic to insulin glargine or any other components. It is contraindicated for the treatment of diabetic ketoacidosis.

Side Effects:

Common side effects may include hypoglycemia, injection site reactions, and allergic reactions. Consult a healthcare provider for a complete list of adverse effects.

Usage Instructions:

Administer Lantus Solostar subcutaneously once daily at the same time each day. Rotate injection sites to prevent lipodystrophy.

Benefits Compared to Analogues:

In comparative studies, Lantus Solostar has shown similar efficacy to other long-acting insulin analogs in controlling blood glucose levels with reduced risk of hypoglycemia. Its once-daily dosing regimen enhances patient compliance.

Suitable Patient Groups:

Lantus Solostar is suitable for children, adults, and elderly patients with diabetes mellitus requiring long-acting insulin therapy.

Storage and Shelf Life:

Store Lantus Solostar in a refrigerator at 2-8°C. Do not freeze. Protect from light. The shelf life of an unopened cartridge is as indicated on the packaging.

Packaging Description:

Lantus Solostar is available in a pack containing 5 cartridges of 3 ml each, delivering 100 IU/ml of insulin glargine solution for subcutaneous injections.

Clinical Evidence and Proven Effectiveness:

Lantus Solostar has demonstrated efficacy in clinical trials, showing improved glycemic control in patients with type 2 diabetes. Research in the Journal of Diabetes Science and Technology supported its long-term benefits in managing diabetes.